Literature DB >> 12604557

Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.

G A Pankuch1, M R Jacobs, P C Appelbaum.   

Abstract

Conventional in vitro methods were used to determine the postantibiotic effects (PAEs), sub-MIC effects (SMEs), and postantibiotic sub-MIC effects (PA-SMEs) of garenoxacin for a range of organisms. The mean PAEs of garenoxacin for pneumococci, staphylococci, and enterococci were 0.3 to 2.2 h. For Escherichia coli and Pseudomonas aeruginosa, the PAEs were 0.9 to 1.6 h. The mean PA-SMEs (0.4 times the MIC) for pneumococci, staphylococci, and enterococci were 3.0 to >10 h, 1.8 to >10.7 h, and 5.8 h, respectively, while those for E. coli and P. aeruginosa were 7.6 and 4.4 h, respectively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604557      PMCID: PMC149305          DOI: 10.1128/AAC.47.3.1140-1142.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Antipneumococcal activity of BMS 284756 compared to those of six other agents.

Authors:  Glenn A Pankuch; Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.

Authors:  Matteo Bassetti; Louise M Dembry; Patricia A Farrel; Deborah A Callan; Vincent T Andriole
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate.

Authors:  R Wise; T Gee; G Marshall; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 6.  The post-antibiotic effect.

Authors:  F M MacKenzie; I M Gould
Journal:  J Antimicrob Chemother       Date:  1993-10       Impact factor: 5.790

Review 7.  The post-antibiotic sub-MIC effect in vitro and in vivo.

Authors:  O Cars; I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

8.  Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development.

Authors:  A M Fix; M A Pfaller; D J Biedenbach; M L Beach; R N Jones
Journal:  Int J Antimicrob Agents       Date:  2001-08       Impact factor: 5.283

9.  Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

Authors:  I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

10.  Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  4 in total

1.  Postantibiotic effect of DX-619 against 16 gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Repurposing Fenamic Acid Drugs To Combat Multidrug-Resistant Neisseria gonorrhoeae.

Authors:  Young Jin Seong; Marwa Alhashimi; Abdelrahman Mayhoub; Haroon Mohammad; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae.

Authors:  Nader S Abutaleb; Ahmed E M Elhassanny; Alessio Nocentini; Chad S Hewitt; Ahmed Elkashif; Bruce R Cooper; Claudiu T Supuran; Mohamed N Seleem; Daniel P Flaherty
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

4.  Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae.

Authors:  Ahmed Elkashif; Mohamed N Seleem
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.